KalVista Reports Positive Phase II Data For Oral HAE Attack Therapy KVD900

Drug Appears Well Positioned Vs. Approved Therapies

 
• By Alaric DeArment
angioedema word cube with background
KalVista announced positive Phase II data for oral HAE drug KVD900. • Source: Shutterstock

More from R&D

More from Scrip